**Temporal Changes in Hypertensive Disorders of Pregnancy and Impact on Cardiovascular and Obstetric Outcomes**

Pensée Wu MD(Res) a, b, Carolyn A Chew-Graham MDc,d, Angela HEM Maas MD PhDe, Lucy C Chappell PhDf, Jessica E Potts PhDa, Martha Gulati MDg, Kelvin P Jordan PhDc, Mamas A Mamas DPhila, h

**Corresponding author**

Pensée Wu

School of Primary, Community and Social Care

Keele University

Staffordshire, ST5 5BG

Tel: +44 (0)1782 732913

Fax: +44 (0) 1782 733911

Email: p.wu@keele.ac.uk

aKeele Cardiovascular Research Group, School of Primary, Community and Social Care, Keele University, Stoke-on-Trent, UK.

bAcademic Unit of Obstetrics and Gynaecology, University Hospital of North Midlands, Stoke-on-Trent, UK.

cSchool of Primary, Community and Social Care, Keele University, Stoke-on-Trent, UK.

dNational Institute for Health Research Collaboration for Leadership in Applied Health Research and Care (CLAHRC) West Midlands, Keele University, Stoke-on-Trent, UK.

eDepartment of Cardiology, Women's Cardiac Health, Radboud University Medical Center, Nijmegen, The Netherlands

fWomen’s Health Academic Centre, King’s College London, London, UK

gDivision of Cardiology, University of Arizona, Phoenix, AZ.

hThe Heart Centre, University Hospital of North Midlands, Stoke-on-Trent, UK.

**Running head**

Hypertensive disorders of pregnancy outcomes.

**Abstract**

Hypertensive disorders of pregnancy (HDP) are a major cause of maternal morbidity. However, short-term outcomes of HDP subgroups remain unknown. Using National Inpatient Sample database, all delivery hospitalizations between 2004 and 2014 with or without HDP (preeclampsia/eclampsia, chronic hypertension, superimposed preeclampsia on chronic hypertension and gestational hypertension) were analysed to examine the association between HDP and adverse in-hospital outcomes. We identified >44 million delivery hospitalizations, within which the prevalence of HDP increased from 8% to 11% over a decade with increasing comorbidity burden. Women with chronic hypertension have higher risks of myocardial infarction, peripartum cardiomyopathy, arrhythmia and stillbirth compared to women with preeclampsia. Out of all HDP subgroups, the superimposed preeclampsia population had the highest risk of stroke (OR 7.83, 95% CI 6.25, 9.80), myocardial infarction (OR 5.20, 95% CI 3.11, 8.69), peripartum cardiomyopathy (OR 4.37, 95% CI 3.64, 5.26), preterm birth (OR 4.65, 95% CI 4.48, 4.83), placental abruption (OR 2.22, 95% CI 2.09, 2.36), and stillbirth (OR 1.78, 95% CI 1.66, 1.92) compared to women without HDP. In conclusion, we are the first to evaluate chronic SH without superimposed preeclampsia as a distinct subgroup in HDP and show that women with chronic SH are at even higher risk of some adverse outcomes compared to women with preeclampsia. In conclusion, the chronic hypertension population, with and without superimposed preeclampsia, is a particularly high risk group and may benefit from increased antenatal surveillance and the use of a prognostic risk assessment model incorporating HDP to stratify intrapartum care.

Key words: hypertensive disorders of pregnancy, preeclampsia, cardiovascular risk factors

**Introduction**

Hypertensive disorders of pregnancy (HDP) have substantial impact on health outcomes,1-3 and are becoming more prevalent. HDP is classified into chronic systemic hypertension (SH) which pre-exists the pregnancy, gestational SH and preeclampsia/eclampsia.4 HDP are known to be associated with both long-term and short-term adverse maternal cardiovascular and obstetric outcomes, such as stroke.5-7 However, the risks of other important maternal outcomes at the time of delivery hospitalization, such as myocardial infarction, heart failure and arrhythmia, remain unknown. Previous literature on HDP and adverse outcomes have primarily focused on the preeclampsia population without considering women with pre-existing chronic SH who did not develop preeclampsia during pregnancy.8, 9 Therefore, we aimed to study the temporal changes in the characteristics, short-term cardiovascular and obstetric outcomes and healthcare costs of women with HDP, stratified by HDP subgroups including chronic SH, over a decade using a national dataset from the United States (U.S.).

**Methods**

 We used the National Inpatient Sample (NIS) database containing hospital discharges in the U.S. between 2004 and 2014. The NIS is the largest all-payer inpatient health care database within the U.S., developed by the Healthcare Cost and Utilization Project (HCUP) sponsored by the Agency for Healthcare Research and Quality (AHRQ).10 The NIS dataset contains hospital information of between 7 and 8 million hospital discharges per year from 2004 onwards. We identified all women with a delivery hospitalization between January 2004 and December 2014 using a previously published protocol (Supplemental Methods).11

HDP was the exposure of interest and divided into chronic SH, gestational SH, preeclampsia and superimposed preeclampsia on chronic SH using codes that were previously published (Supplemental Table S1A).12-14 These subgroups were chosen in accordance with the International Society for the Study of Hypertension in Pregnancy classification.8 Selected in-hospital adverse cardiovascular and obstetric outcomes were identified from the dataset using ICD-9-CM codes in previous literature (Supplemental Table S1B).12-20 We also examined the length of stay (LOS) and the total charge of hospitalization in NIS (Supplemental methods). To assess temporal trends, the years were grouped as follows: 2004-2007, 2008-2011, 2012-2014. Covariates on patient demographics, comorbidities and obstetric factors for each hospital discharge were extracted (Supplemental Methods). The ICD-9-CM codes used to extract comorbidities were from previous publications (Supplemental Table S1C).18, 19, 21, 22

The Stata/MP version 14.0 statistical package was used to perform all analyses. Continuous variables are presented as median and interquartile range, and categorical data are presented as number and percentage. For variables that had less than 0.5% missing data overall, the episodes with missing data were dropped as data was assumed to be missing at random. The race and ethnicity and median income of ZIP code variables had 17% and 21% missing data, respectively, and a missing category was used in these two variables. Furthermore, sensitivity analyses were performed to assess the effect of excluding observations with missing race and ethnicity or median ZIP code income. We conducted multivariable analyses to determine the association of HDP and the adverse cardiovascular and obstetric outcomes of interest. Logistic regression models were fitted using the maximum likelihood estimation. The multivariable analyses were adjusted for all potential confounders in steps as follows: demographics alone, comorbidities alone, obstetric factors alone, and finally adjustments for demographics, comorbidities and obstetric factors in the full model. The RECORD checklist,23 an extension of STROBE checklist, is shown in Supplemental Table S2 to summarise our study.

**Results**

A total of 44,276,975 delivery hospitalization episodes between 2004 and 2014 were identified (Figure 1). The proportion of HDP within the delivery hospitalization population increased over the years from 8.4% in 2004 to 10.9% in 2014, mainly driven by increases in the chronic SH and gestational SH groups (Figure 2, Supplemental Table S3).

Table 1 shows the characteristics of women with delivery hospitalizations stratified into women who did not have HDP and groups of women who had HDP. Within the HDP population, preeclampsia was the most common diagnosis, followed by chronic SH. Compared with women who did not have HDP, women in HDP groups generally had a higher proportion of black women, women residing in areas below the lowest quartile of household income, and with weekday admissions. These differences were particularly pronounced when comparing the characteristics of the superimposed preeclampsia group with the non-HDP group. The HDP groups had a higher prevalence of majority of the cardiovascular risk factors and comorbidities, compared to the non-HDP group. Generally, the superimposed preeclampsia and chronic SH groups had the highest prevalence of risk factors and comorbidities out of all groups of HDP. Over the 11-year period, the average maternal age increased with an increasing prevalence of recorded comorbid conditions in women having delivery hospitalizations (Supplemental Table S4). Figure 3 shows the temporal changes in the prevalence of selected cardiovascular risk factors during hospitalisation, stratified by non-HDP and HDP groups. The prevalence increased over time in all groups, with the superimposed preeclampsia group generally having the highest recorded prevalence out of all groups.

The crude event rates for adverse cardiovascular and obstetric outcomes in HDP groups are presented in Supplemental Table S5. These outcomes occurred most frequently in women with superimposed preeclampsia compared with other HDP groups, apart from postpartum hemorrhage. Over the 11-year study period, the rate of most adverse outcomes remained static in all groups, except for reducing rates of maternal mortality and preterm birth and an increasing rate of postpartum hemorrhage (Supplemental Table S6).

 We conducted multivariable analyses to examine the independent prognostic association of HDP with adverse outcomes (Table 2). Women with superimposed preeclampsia had the highest risk for all outcomes compared to the non-HDP group, except for maternal mortality and postpartum hemorrhage in which women with preeclampsia had the highest risk (Figures 4A, I); and for arrhythmia where women with chronic SH had the highest risk (Figure 4E). Women with chronic SH had a higher adjusted risk for myocardial infarction, peripartum cardiomyopathy, arrhythmia and stillbirth compared with women with preeclampsia (Figures 4B, D and H). As shown in Table 2, for the cardiovascular outcomes, confounding was mainly from comorbidities and secondly from demographic factors. In contrast, for the obstetric outcomes, confounding was caused by a mixture of all three factors. However, the associations between HDP and adverse cardiovascular and obstetric outcomes remained significant, even with full adjustment. Supplemental Table S7 shows the ORs for the individual comorbidity within the multivariate models. In addition, sensitivity analyses were conducted to examine for the effects of excluding records with missing data (Supplemental Table S8) and for the effects of clustering in hospitals (data not shown). This showed no important changes in the ORs.

Supplemental Figure S1 illustrate the temporal changes in the strength of association of adverse clinical outcomes between 2004 and 2014 in the HDP groups compared to the non-HDP group. There was little change except for preterm birth where the strength of association reduced between the 2004-2007 and 2012-2014 periods in all HDP groups (Supplemental Figure S1E). These findings were further confirmed by additional analyses within each HDP group that compared associations by year (data not shown).

After excluding women who died, those with superimposed preeclampsia had the longest LOS of 4 days, compared with the other HDP groups and the non-HDP group. These figures remained similar across the study period (Supplemental Figure S2). For healthcare costs, women with superimposed preeclampsia required double the treatment cost compared with women without HDP. However, over the years the healthcare costs have remained static in all groups between 2004 and 2014 (Supplemental Figure S3).

**Discussion**

In this analysis of over 44 million delivery hospitalizations including over 4.2 million HDP hospitalizations, we demonstrate that HDP is increasingly prevalent in an increasingly complex population of women who are older and with more comorbidities. Our study is the first to evaluate chronic SH without superimposed preeclampsia as a distinct HDP subgroup and show that women with chronic SH have even higher risks for myocardial infarction and arrhythmia during delivery hospitalizations compared to women with preeclampsia. We are the first to quantify the odds of short-term myocardial infarction and arrhythmia in HDP population, and to assess Elixhauser comorbidities in the context of HDP using a national dataset.

Our study highlights women with chronic SH is a novel risk population as many previous studies on HDP have specifically excluded women with chronic SH. 8, 9, 24 We showed that the superimposed preeclampsia on chronic SH group has the highest ORs out of all HDP groups for the majority of adverse outcomes we studied, whilst the chronic SH only group had higher risks for many of the outcomes we report compared with the preeclampsia only group. The underlying mechanisms may be that women with chronic SH have had a longer exposure to adverse cardiovascular changes, commencing from preconception and throughout pregnancy, compared to women with preeclampsia only, who have a relatively shorter exposure occurring from onset of disease (after 20 weeks of gestation) in pregnancy. Therefore, women with chronic SH have had a longer period for cardiovascular pathology to develop.

We are the first to demonstrate that superimposed preeclampsia and chronic SH are independently associated with a 5-fold increased risk of in-hospital myocardial infarction and double the odds of peripartum arrhythmia, respectively. We also illustrate that, except for the gestational SH subgroup, HDP is associated with 1.3- to 7.8-fold increased risk of adverse maternal outcomes, including preterm birth, postpartum hemorrhage, stillbirth, placental abruption, mortality, peripartum cardiomyopathy and stroke. For most of the adverse outcomes we examined, we were unable to directly compare our levels of risks with other NIS studies as they used different study populations.12, 25-27 For maternal mortality, stroke and stillbirth outcomes, studies which compared women with and without chronic SH reported lower levels of odds ratios than those from our study.14, 28 This may be due to our more comprehensive approach to adjustment for potential confounders.

There is a gap in knowledge regarding whether HDP is an independent risk factor for adverse cardiovascular outcomes, or an early marker of women with high risk factors for developing these diseases. Through a novel approach of comparing different adjusted multivariate models, we determined that comorbidities were the main confounders of the adverse cardiovascular outcomes, while a mix of demographic, comorbidities and obstetric factors contributed to the adverse obstetric outcomes. This reflects their underlying differences in pathophysiology and implies that different strategies to improve cardiovascular and obstetric health is needed. For example, identification of multimorbid women who are at risk may improve cardiovascular outcomes within the HDP population.

One previous study has examined HDP within the NIS and showed an event rate of 8.2% in 2006,28 compared with our rate of 10.9% in 2014. Our analysis includes the most recent data, considers superimposed preeclampsia separately, and includes additional outcomes and comorbidities. Our HDP population characteristics is in keeping with literature, i.e. of black ethnicity, of lower income, and with more comorbidities, compared to women without HDP.29, 30 However, unlike our study, the previous study only considered cardiovascular disorders as a composite condition, did not quantify risks of adverse outcomes, and excluded women with chronic SH and the majority of the Elixhauser comorbid conditions.

Using the largest publicly available database in the world with real world hospital outcomes, the strength of this study includes the large number of hospital delivery episodes that provides the statistical power to study rare adverse cardiovascular outcomes such as mortality and myocardial infarction within HDP subgroups. With over 4.2 million HDP delivery hospitalizations over a decade, we were also able to examine and provide meaningful interpretation of the temporal trends in prevalence, comorbidities, and associated adverse clinical outcomes, as well as the patterns in health economic indicators.

Our analysis has a number of limitations including those present in all retrospective studies of large administrative databases, such as coding errors and under-reporting of comorbidities and secondary diagnoses during hospitalization. Our outcomes were restricted to only in-hospital outcomes as post-discharge information was unavailable. With the lack of data on timing of events, we were unable to conduct time to events nor effects of chronicity of comorbidity analyses. Furthermore, this database does not contain pharmacotherapy data which would have been informative for accurate classification of HDP groups and comorbid conditions, as well as the impact of those treated or untreated for chronic SH. We did not consider mortality as a competing risk for myocardial infarction and stroke, which could have contributed to the cause of mortality. As we have not adjusted for multiple testing, some of the statistically significant findings may be due to chance. Finally, for the temporal analyses, the accuracy may have improved over time due to guidelines or incentives for better coding.

In conclusion, in this analysis of over 4.2 million HDP delivery hospitalizations, we demonstrated that HDP is independently associated with a 5-fold increased risk of peripartum myocardial infarction and that women with chronic SH have even higher risks for specific adverse outcomes compared to women with preeclampsia. Women with chronic SH may benefit from increased antenatal surveillance to improve outcomes. The development of a prognostic risk assessment tool including HDP may be useful for stratifying intrapartum care.

**Acknowledgement**

PW is funded by a National Institute for Health Research (NIHR) Transitional Research Fellowship, United Kingdom. LCC is supported by the NIHR Research Professorship, (RP-2014-05-019), United Kingdom. CCG is part-funded by West Midlands Collaboration for Leadership in Applied Health Research and Care, United Kingdom. This paper presents independent research funded by the NIHR. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health and Social Care. The funders had no involvement in the conduct of this research.

**References**

1. Leffert LR, Clancy CR, Bateman BT, Bryant AS and Kuklina EV. Hypertensive Disorders and Pregnancy-Related Stroke: Frequency, Trends, Risk Factors, and Outcomes. *Obstet Gynecol*. 2015;125:124-131.

2. Grear KE and Bushnell CD. Stroke and Pregnancy: clinical presentation, evaluation, treatment, and epidemiology. *Clin Obstet Gynecol*. 2013;56:350-359.

3. Premkumar A, Baer RJ, Jelliffe-Pawlowski LL and Norton ME. Hypertensive Disorders of Pregnancy and Preterm Birth Rates among Black Women. *Am J Perinatol.* 2019; 36:148-154.

4. Brown MA, Magee LA, Kenny LC, Karumanchi SA, McCarthy FP, Saito S, Hall DR, Warren CE, Adoyi G and Ishaku S. The Hypertensive Disorders of Pregnancy: ISSHP classification, diagnosis & management recommendations for international practice. *Pregnancy Hypertens.* 2018; 13:291-310.

5. Wu P, Haththotuwa R, Kwok CS, Babu A, Kotronias RA, Rushton C, Zaman A, Fryer AA, Kadam U, Chew-Graham CA and Mamas MA. Preeclampsia and Future Cardiovascular Health: a systematic review and meta-analysis. *Circ Cardiovasc Qual Outcomes.* 2017; 10: pii: e003497.

6. Bushnell C and Chireau M. Preeclampsia and Stroke: Risks during and after Pregnancy. *Stroke Res Treat*. 2011; 2011:858134.

7. Harmon QE, Huang L, Umbach DM, Klungsoyr K, Engel SM, Magnus P, Skjaerven R, Zhang J and Wilcox AJ. Risk of Fetal Death with Preeclampsia. *Obstet Gynecol*. 2015; 125:628-635.

8. Kenny LC, Black MA, Poston L, Taylor R, Myers JE, Baker PN, McCowan LM, Simpson NA, Dekker GA, Roberts CT, Rodems K, Noland B, Raymundo M, Walker JJ and North RA. Early Pregnancy Prediction of Preeclampsia in Nulliparous Women, Combining Clinical Risk and Biomarkers: the Screening for Pregnancy Endpoints (SCOPE) international cohort study. *Hypertension*. 2014; 64:644-652.

9. Magnussen EB, Vatten LJ, Smith GD and Romundstad PR. Hypertensive Disorders in Pregnancy and Subsequently Measured Cardiovascular Risk Factors. *Obstet Gynecol*. 2009; 114: 961-970.

10. HCUP. National Inpatient Sample (NIS). Healthcare Cost and Utilization Project (HCUP). 2012; Available at: https://hcup-us.ahrq.gov/nisoverview.jsp. Accessed 29th October 2019.

11. Kuklina E, K Whiteman M, Hillis S, J Jamieson D, F Meikle S, Posner S and A Marchbanks P. An Enhanced Method for Identifying Obstetric Deliveries: Implications for Estimating Maternal Morbidity. *Matern Child Health J.* 2008; 12:469-477.

12. Lima FV, Parikh PB, Zhu J, Yang J and Stergiopoulos K. Association of Cardiomyopathy with Adverse Cardiac Events in Pregnant Women at the Time of Delivery. *JACC Heart Fail*. 2015; 3:257-266.

13. Stevens W, Shih T, Incerti D, Ton TGN, Lee HC, Peneva D, Macones GA, Sibai BM and Jena AB. Short-term Costs of Preeclampsia to the United States Health Care System. *Am J Obstet Gynecol*. 2017; 217:237-248.e16.

14. Bateman BT, Bansil P, Hernandez-Diaz S, Mhyre JM, Callaghan WM and Kuklina EV. Prevalence, Trends, and Outcomes of Chronic Hypertension: a nationwide sample of delivery admissions. *Am J Obstet Gynecol*. 2012; 206:134.e1-8.

15. Kuklina EV and Callaghan WM. Cardiomyopathy and Other Myocardial Disorders among Hospitalizations for Pregnancy in the United States: 2004-2006. *Obstet Gynecol*. 2010; 115:93-100.

16. Collins RT, 2nd, Chang D, Sandlin A, Goudie A and Robbins JM. National In-Hospital Outcomes of Pregnancy in Women With Single Ventricle Congenital Heart Disease. *Am J Cardiol*. 2017; 119:1106-1110.

17. Vaidya VR, Arora S, Patel N, Badheka AO, Patel N, Agnihotri K, Billimoria Z, Turakhia MP, Friedman PA, Madhavan M, Kapa S, Noseworthy PA, Cha YM, Gersh B, Asirvatham SJ and Deshmukh AJ. Burden of Arrhythmia in Pregnancy. *Circulation*. 2017; 135:619-621.

18. Zhong QY, Gelaye B, Smoller JW, Avillach P, Cai T and Williams MA. Adverse Obstetric Outcomes during Delivery Hospitalizations Complicated by Suicidal Behavior among US Pregnant Women. *PLOS ONE*. 2018; 13:e0192943.

19. Mogos MF, Piano MR, McFarlin BL, Salemi JL, Liese KL and Briller JE. Heart Failure in Pregnant Women: A Concern Across the Pregnancy Continuum. *Circ Heart Fail*. 2018; 11:e004005.

20. Rougerie M, Czuzoj-Shulman N and Abenhaim HA. Diabetic Ketoacidosis among Pregnant and Non-pregnant Women: a comparison of morbidity and mortality. *J Matern Fetal Neonatal Med*. 2019; 32: 2649-2652.

21. Agarwal MA, Garg L, Lavie CJ, Reed GL and Khouzam RN. Impact of Family History of Coronary Artery Disease on in-hospital Clinical Outcomes in ST-segment Myocardial Infarction. *Ann Transl Med*. 2018;6:3.

22. Smilowitz NR, Gupta N, Guo Y, Beckman JA, Bangalore S and Berger JS. Trends in Cardiovascular Risk Factor and Disease Prevalence in Patients undergoing Non-cardiac Surgery. *Heart*. 2018; 104: 1180-1186.

23. Benchimol EI, Smeeth L, Guttmann A, Harron K, Moher D, Petersen I, Sørensen HT, von Elm E, Langan SM and RECORD Working Committee. The REporting of studies Conducted using Observational Routinely-collected health Data (RECORD) Statement. *PLOS Med*. 2015; 12:e1001885.

24. Buchbinder A, Sibai BM, Caritis S, Macpherson C, Hauth J, Lindheimer MD, Klebanoff M, Vandorsten P, Landon M, Paul R, Miodovnik M, Meis P and Thurnau G. Adverse Perinatal Outcomes are Significantly Higher in Severe Gestational Hypertension than in Mild Preeclampsia. *Am J Obstet Gynecol*. 2002; 186:66-71.

25. Leffert LR, Clancy CR, Bateman BT, Bryant AS and Kuklina EV. Hypertensive Disorders and Pregnancy-Related Stroke: frequency, trends, risk factors, and outcomes. *Obstet Gynecol*. 2015; 125:124-131.

26. Smilowitz NR, Gupta N, Guo Y, Zhong J, Weinberg CR, Reynolds HR and Bangalore S. Acute Myocardial Infarction During Pregnancy and the Puerperium in the United States. *Mayo Clin Proc*. 2018; 93: 1404-1414.

27. Schlichting LE, Insaf TZ, Zaidi AN, Lui GK and Van Zutphen AR. Maternal Comorbidities and Complications of Delivery in Pregnant Women With Congenital Heart Disease. *J Am Coll Cardiol*. 2019; 73:2181-2191.

28. Kuklina EV, Ayala C and Callaghan WM. Hypertensive Disorders and Severe Obstetric Morbidity in the United States. *Obstet Gynecol*. 2009; 113:1299-306.

29. Fingar K, Mabry-Hernandez I, Ngo-Metzger Q, Wolff T, Steiner C and Elixhauser A. Delivery Hospitalizations Involving Preeclampsia and Eclampsia, 2005-2014. HCUP Statistical Brief #222. Apr 2017. Available at: https://www.hcup-us.ahrq.gov/reports/statbriefs/sb222-Preeclampsia-Eclampsia-Delivery-Trends.pdf. Accessed on 29th October 2019.

30. Gyamfi-Bannerman C, Pandita A, Wright JD, Siddiq Z, D'Alton ME and Friedman AM. 434: Racial Disparities in Preeclampsia Outcomes at delivery. *Am J Obstet Gynecol*. 2019; 220:S294.

**Figure Legends**

Figure 1. Flow diagram of included/excluded records.

Figure 2. Percentage of delivery episodes recorded with hypertensive disorders of pregnancy 2004 – 2014. PE, preeclampsia. SH, hypertension.

Figure 3. Cardiovascular risk factors and comorbidities in hypertensive disorders of pregnancy between 2004 and 2014 (A) Previous stroke (B) Dyslipidemia (C) Renal failure (D) Congenital heart disease (E) Diabetes (F) Obesity, (G) Smoking, and (H) Alcohol abuse. PE, preeclampsia. SH, hypertension.

Figure 4. Association between subgroups of hypertensive disorders of pregnancy and adverse outcomes.